144 related articles for article (PubMed ID: 23242173)
1. KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.
Dijkstra JR; Heideman DA; Meijer GA; Boers JE; 't Hart NA; Diebold J; Hirschmann A; Hoefler G; Winter G; Miltenberger-Miltenyi G; Pereira SV; Richman SD; Quirke P; Rouleau EL; Guinebretiere JM; Tejpar S; Biesmans B; van Krieken JH
Virchows Arch; 2013 Jan; 462(1):39-46. PubMed ID: 23242173
[TBL] [Abstract][Full Text] [Related]
2. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.
Bellon E; Ligtenberg MJ; Tejpar S; Cox K; de Hertogh G; de Stricker K; Edsjö A; Gorgoulis V; Höfler G; Jung A; Kotsinas A; Laurent-Puig P; López-Ríos F; Hansen TP; Rouleau E; Vandenberghe P; van Krieken JJ; Dequeker E
Oncologist; 2011; 16(4):467-78. PubMed ID: 21441573
[TBL] [Abstract][Full Text] [Related]
3. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.
Lee S; Brophy VH; Cao J; Velez M; Hoeppner C; Soviero S; Lawrence HJ
Virchows Arch; 2012 Feb; 460(2):141-9. PubMed ID: 22173329
[TBL] [Abstract][Full Text] [Related]
4. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.
Feigelson HS; Goddard KA; Johnson MA; Funk KC; Rahm AK; Kauffman TL; Chitale DA; Le Marchand L; Richards CS
BMC Res Notes; 2012 Apr; 5():196. PubMed ID: 22534075
[TBL] [Abstract][Full Text] [Related]
5. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.
Sundström M; Edlund K; Lindell M; Glimelius B; Birgisson H; Micke P; Botling J
BMC Cancer; 2010 Dec; 10():660. PubMed ID: 21122130
[TBL] [Abstract][Full Text] [Related]
6. Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer.
Kristensen LS; Kjeldsen TE; Hager H; Hansen LL
BMC Cancer; 2012 Nov; 12():548. PubMed ID: 23173730
[TBL] [Abstract][Full Text] [Related]
7. Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme.
Dequeker E; Ligtenberg MJ; Vander Borght S; van Krieken JH
Virchows Arch; 2011 Aug; 459(2):155-60. PubMed ID: 21701884
[TBL] [Abstract][Full Text] [Related]
8. Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis.
Dijkstra JR; Opdam FJ; Boonyaratanakornkit J; Schönbrunner ER; Shahbazian M; Edsjö A; Hoefler G; Jung A; Kotsinas A; Gorgoulis VG; López-Ríos F; de Stricker K; Rouleau E; Biesmans B; van Krieken JH
J Mol Diagn; 2012; 14(3):187-91. PubMed ID: 22414609
[TBL] [Abstract][Full Text] [Related]
9. Setting future standards for KRAS testing in colorectal cancer.
van Krieken H; Tol J
Pharmacogenomics; 2009 Jan; 10(1):1-3. PubMed ID: 19102707
[No Abstract] [Full Text] [Related]
10. Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection.
Ibrahem S; Seth R; O'Sullivan B; Fadhil W; Taniere P; Ilyas M
Int J Exp Pathol; 2010 Dec; 91(6):500-5. PubMed ID: 21199003
[TBL] [Abstract][Full Text] [Related]
11. KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13.
Bihl MP; Hoeller S; Andreozzi MC; Foerster A; Rufle A; Tornillo L; Terracciano L
Diagn Mol Pathol; 2012 Mar; 21(1):14-23. PubMed ID: 22306671
[TBL] [Abstract][Full Text] [Related]
12. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
[TBL] [Abstract][Full Text] [Related]
13. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
14. EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.
Thunnissen E; Bovée JV; Bruinsma H; van den Brule AJ; Dinjens W; Heideman DA; Meulemans E; Nederlof P; van Noesel C; Prinsen CF; Scheidel K; van de Ven PM; de Weger R; Schuuring E; Ligtenberg M
J Clin Pathol; 2011 Oct; 64(10):884-92. PubMed ID: 21947301
[TBL] [Abstract][Full Text] [Related]
15. [Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].
Enlund F; Helenius G; Palmqvist R; Edsjö A; Sundström M
Lakartidningen; 2010 Feb 3-9; 107(5):255-9. PubMed ID: 20297566
[No Abstract] [Full Text] [Related]
16. Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing.
Bando H; Tsuchihara K; Yoshino T; Kojima M; Ogasawara N; Fukushima H; Ochiai A; Ohtsu A; Esumi H
Jpn J Clin Oncol; 2011 Feb; 41(2):239-44. PubMed ID: 21113056
[TBL] [Abstract][Full Text] [Related]
17. Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.
Carotenuto P; Roma C; Cozzolino S; Fenizia F; Rachiglio AM; Tatangelo F; Iannaccone A; Baron L; Botti G; Normanno N
Int J Oncol; 2012 Feb; 40(2):378-84. PubMed ID: 21971641
[TBL] [Abstract][Full Text] [Related]
18. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
[TBL] [Abstract][Full Text] [Related]
19. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.
Dono M; Massucco C; Chiara S; Sonaglio C; Mora M; Truini A; Cerruti G; Zoppoli G; Ballestrero A; Truini M; Ferrarini M; Zupo S
Mol Med; 2013 Feb; 18(1):1519-26. PubMed ID: 23255073
[TBL] [Abstract][Full Text] [Related]
20. A comparability study of 5 commercial KRAS tests.
Oliner K; Juan T; Suggs S; Wolf M; Sarosi I; Freeman DJ; Gyuris T; Baron W; Bakker A; Parker A; Patterson SD
Diagn Pathol; 2010 Apr; 5():23. PubMed ID: 20398393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
